Literature DB >> 11433341

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

D Kirn1, R L Martuza, J Zwiebel.   

Abstract

In the search for novel cancer therapies that can be used in conjunction with existing treatments, one promising area of research is the use of viral vectors and whole viruses. This review describes the underlying biological principles and current status of the field, outlines approaches for improving clinical effectiveness and discusses the unique safety and regulatory issues surrounding viral therapies.

Entities:  

Mesh：

Year:  2001        PMID： 11433341     DOI： 10.1038/89901

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  127 in total

1.  Bak and Bax function to limit adenovirus replication through apoptosis induction.

Authors:  Andrea Cuconati; Kurt Degenhardt; Ramya Sundararajan; Alan Anschel; Eileen White
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 2.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

3.  Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells.

Authors:  C-Q Su; J Sham; H-B Xue; X-H Wang; D Chua; Z-F Cui; L-H Peng; L-F Li; L-H Jiang; M-C Wu; Q-J Qian
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-09       Impact factor: 4.553

4.  The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53.

Authors:  Jose G Teodoro; Destin W Heilman; Albert E Parker; Michael R Green
Journal:  Genes Dev       Date:  2004-08-15       Impact factor: 11.361

5.  An intravenous stimulus package for oncolytic virotherapy.

Authors:  Richard Vile; Alan Melcher
Journal:  Mol Ther       Date:  2011-11       Impact factor: 11.454

6.  Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.

Authors:  Rohann J M Correa; Monica Komar; Jessica G K Tong; Milani Sivapragasam; Masmudur M Rahman; Grant McFadden; Gabriel E Dimattia; Trevor G Shepherd
Journal:  Gynecol Oncol       Date:  2012-02-01       Impact factor: 5.482

7.  Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Authors:  Saw See Hong; Nagy A Habib; Laure Franqueville; Steen Jensen; Pierre A Boulanger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.

Authors:  Thi Lien-Anh Nguyên; Hesham Abdelbary; Meztli Arguello; Caroline Breitbach; Simon Leveille; Jean-Simon Diallo; Amber Yasmeen; Tarek A Bismar; David Kirn; Theresa Falls; Valerie E Snoulten; Barbara C Vanderhyden; Joel Werier; Harold Atkins; Markus J V Vähä-Koskela; David F Stojdl; John C Bell; John Hiscott
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

10.  Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

Authors:  Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Jose Pulido; Candice Willmon; Matt Coffey; Peter Selby; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.